Ovid Therapeutics Inc
F:1OT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ovid Therapeutics Inc
F:1OT
|
US |
|
N
|
National Fuel Gas Co
SWB:NFG
|
US |
|
F
|
Fresenius Medical Care AG
XHAN:FME
|
DE |
|
B
|
Beowulf Mining PLC
XBER:B4E
|
UK |
|
Energiekontor AG
XETRA:EKT
|
DE |
|
A
|
Aspocomp Group Oyj
SWB:ACN
|
FI |
|
G
|
Goldplat PLC
SWB:G7N
|
UK |
|
S
|
SLR Investment Corp
SWB:ZSL
|
US |
Ovid Therapeutics Inc
Ovid Therapeutics is a drug development company focused on rare brain disorders, especially severe epilepsies and other neurological diseases. It does not sell consumer products; instead, it works on experimental medicines designed to change how nerve cells signal in the brain, with a focus on conditions that have few good treatment options. The company makes money the way many biotech firms do: by raising capital, then funding research, clinical trials, and regulatory work for its drug candidates. If a program succeeds, Ovid can earn value through future drug sales, partnerships, or licensing deals, rather than through a large direct sales force today. What makes Ovid’s business different is its narrow focus on difficult, orphan neurological diseases where standard treatments often fall short. That puts it in a specialized corner of biotech, where the main job is to move a few carefully chosen therapies through testing and, if they work, hand them off into the commercial drug market.
Ovid Therapeutics is a drug development company focused on rare brain disorders, especially severe epilepsies and other neurological diseases. It does not sell consumer products; instead, it works on experimental medicines designed to change how nerve cells signal in the brain, with a focus on conditions that have few good treatment options.
The company makes money the way many biotech firms do: by raising capital, then funding research, clinical trials, and regulatory work for its drug candidates. If a program succeeds, Ovid can earn value through future drug sales, partnerships, or licensing deals, rather than through a large direct sales force today.
What makes Ovid’s business different is its narrow focus on difficult, orphan neurological diseases where standard treatments often fall short. That puts it in a specialized corner of biotech, where the main job is to move a few carefully chosen therapies through testing and, if they work, hand them off into the commercial drug market.
Pipeline: Ovid announced regulatory clearance for OV4071, the first oral KCC2 direct activator, and will initiate a Phase I in Q2 2026 followed by a ketamine challenge later this year and proof-of-concept patient studies late 2026/early 2027.
OV329 safety: The 7 mg dose of OV329 showed no treatment-related serious adverse events and no ophthalmic safety signals in healthy volunteers; ophthalmic monitoring will continue into later studies.
Dosing / pharmacology: Management targets ~50%–60% GABA-aminotransferase inhibition; human plasma exposure range modeled at roughly "16-nanogram per hour per ml to 120" and both 5 mg and 7 mg doses fall in the target exposure range.
Pediatric expansion: PIPE financing enables additive programs for OV329 in infantile spasms and Tuberous Sclerosis Complex (TSC) with open-label signal-finding studies and potential combined pivotal Phase II/III designs.
Financing / runway: As of Dec 31, 2025 cash was "$90.4 million"; announced PIPE gross proceeds of "$60 million"; net PIPE gives runway into the second half of 2028; pro forma with potential Series A warrant exercises (triggered by OV4071 clearance) runs "well into 2029" (potential warrant proceeds greater than "$53 million").
Milestone cadence: OV329 Phase II randomized placebo-controlled study starts Q2 2026; open-label photosensitivity study later in 2026; TSC and infantile spasms open-label signal-finding studies starting this year with step-down into pediatrics; KCC2 Day scheduled April 14 to present more data.
Commercial opportunity context: Management highlighted that vigabatrin (Sabril) had U.S. peak sales of "$320 million" and believes a safer GABA-AT inhibitor could support earlier and longer use and materially larger commercial uptake.
